Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated SCC

Summary

This pilot trial studies how rigsertib sodium works in treating patients with Recessive Dystrophic Epidermolysis bullosa (RDEB) with locally advanced Squamous Cell Carcinoma (SCC). Rigosertib may selectively target Epidermolysis bullosa (EB) cancer cells while leaving normal EB cells unaffected.

Timeline

Start

2021-08-24

Primary completion

2025-05-05

Completion

2025-05-05

Drugs

Indications